A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation

Heart and Vessels

Volumn 31, Issue 7, 2016, Pages 1206-1208

  Ko, Toshiyuki ^a   Hatano, Masaru ^a   Nitta, Daisuke ^a   Muraoka, Hironori ^a   Minatsuki, Shun ^a   Imamura, Teruhiko ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Yao, Atsushi ^a   Kinugawa, Koichiro ^a   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Interferon; Pulmonary arterial hypertension; Treprostinil

Indexed keywords

ALPHA INTERFERON; AMBRISENTAN; BERAPROST; BRAIN NATRIURETIC PEPTIDE; TADALAFIL; TREPROSTINIL; ANTIHYPERTENSIVE AGENT; IMMUNOLOGIC FACTOR; PROSTACYCLIN;

ADULT; ARTICLE; BLOOD EXAMINATION; CASE REPORT; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FLUID RETENTION; HEART CATHETERIZATION; HEART RIGHT VENTRICLE HYPERTROPHY; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ARTERIAL PRESSURE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG EFFECTS; HYPERTENSION, PULMONARY; LIVING DONOR; PATHOPHYSIOLOGY; PULMONARY ARTERY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PULMONARY ARTERY; TADALAFIL; TREATMENT OUTCOME;

EID: 84931073247     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-015-0701-1     Document Type: Article

References (15)

1. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655–1665
2. Amano H, Toyoda S, Arikawa T, Inami S, Otani N, Nishi Y, Kitagawa Y, Taguchi I, Abe S, Inoue T (2013) Left ventricular function in pulmonary hypertension. Heart Vessels 28(4):505–509
3. George MG, Schieb LJ, Ayala C, Talwalkar A, Levant S (2014) Pulmonary hypertension surveillance: United States, 2001–2010. Chest 146(2):476–495
4. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–D41
5. Savale L, Sattler C, Günther S, Montani D, Chaumais MC, Perrin S, Jaïs X, Seferian A, Jovan R, Bulifon S, Parent F, Simonneau G, Humbert M, Sitbon O (2014) Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 44(6):1627–1634
6. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135(1):44–53
7. Erol MK, Erol S, Koruk M, Ertek M, Bozkurt E (2004) Effects of interferon-alpha therapy on cardiac function in patients with chronic hepatitis B infection. Heart Vessels 19(6):263–266
8. Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH (2010) Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 55(6):1785–1790
9. Fruehauf S, Steiger S, Topaly J, Ho AD (2001) Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 80(5):308–310
10. George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR, Mitchell JA (2012) Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ 2(4):501–504
11. George PM, Oliver E, Dorfmuller P, Dubois OD, Reed DM, Kirkby NS, Mohamed NA, Perros F, Antigny F, Fadel E, Schreiber BE, Holmes AM, Southwood M, Hagan G, Wort SJ, Bartlett N, Morrell NW, Coghlan JG, Humbert M, Zhao L, Mitchell JA (2014) Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 114(4):677–688
12. Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM (2011) Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 30(9):982–989
13. Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, White RJ, TRUST Study Group (2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 29(2):137–149
14. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, Barst RJ (2006) Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129(3):683–688
15. Hatano M, Yamada H, Fukuda K, Yoshioka K, Funauchi M, Kuwana M, Sata M, Taniguchi M, Nakanishi N, Saito T, Saji T, Sasayama S (2014) Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension. Heart Vessels. doi:10.1007/s00380-014-0544-1